Drugs / RAF265
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01352273 | Jun 2011 → Sep 2013 | cancer | Array BioPharma | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00304525 | Apr 2006 → Nov 2013 | metastatic melanoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAF265 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01352273 ↗ |
| Known as | CHIR-265 | “A Phase I/II, Open-label, Dose Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RAF265 (CHIR-265)Administered Orally to Patients With Locally...” NCT00304525 ↗ |
| Known as | NVP-RAF265 | ChEMBL registry synonym — accepted as the source's own label CHEMBL558752 ↗ |
| Action | Inhibit | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL558752 ↗2“potent inhibitory activity against B-Raf kinase” NCT00304525 ↗ “Serine/threonine-protein kinase B-raf inhibitor” CHEMBL558752 ↗ |
| Modality | Small molecule | “RAF265 is a novel, orally active, small molecule with potent inhibitory activity against B-Raf kinase and additional antiangiogenic activity through inhibition of vascular...” NCT00304525 ↗ |
| Route | Oral | “administered orally” NCT00304525 ↗ |
| Target | BRAF | “Serine/threonine-protein kinase B-raf inhibitor” CHEMBL558752 ↗ |
| Target | KDR | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL558752 ↗ |